New drug aims to stop dangerous blood side effect in breast cancer patients
NCT ID NCT07243418
Summary
This study is testing whether a drug called hetrombopag can prevent or reduce severe drops in platelet counts (thrombocytopenia) caused by a specific type of breast cancer treatment known as ADC drugs. It will involve 72 breast cancer patients who are either starting this treatment or who had low platelets during a previous cycle. The goal is to see if taking hetrombopag helps patients avoid this serious side effect and continue their cancer therapy safely.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.